Calithera Biosciences Reports Third Quarter 2015 Financial Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Calithera Biosciences (CALA) Reports Q3 Loss of $0.49/Share
November 10, 2015 9:43 AM ESTCalithera Biosciences (NASDAQ: CALA) reported Q3 EPS of ($0.49), versus ($16.85) reported last year.
Anticipated Upcoming Milestones
Hematologic Phase 1 clinical trial data by year end 2015Initiation of six CB-839 combination expansion cohorts by year end 2015CB-839 combination therapy data in... MoreCalithera Biosciences (CALA) Files $150M Common Stock Shelf
November 10, 2015 9:41 AM ESTCalithera Biosciences (NASDAQ: CALA) filed a registration with the U.S. SEC to sell up to $150 million worth of common stock.
... MoreLeerink Partners Reiterates Outperform on Calithera Biosciences (CALA) Following 3Q
November 10, 2015 7:00 AM ESTLeerink Partners reiterated an Outperform rating and $13.00 price target on Calithera Biosciences (NASDAQ: CALA) following the company's 3Q earnings report. CALA reported 3Q15 EPS of ($0.49), slightly better than consensus estimates of ($0.54).
Analyst Paul Matteis commented, "After the close, CALA reported 3Q15 EPS of ($0.49), in-line with... More
